PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Demoxytocin→

Demoxytocin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
113-78-0
Molecular formula
C43H65N11O12S2
Molecular weight
992.2 g/mol
Drug class
Synthetic oxytocin analogueuterotonic cyclic peptide
Mechanism of action
Activates oxytocin receptors on uterine smooth muscle and mammary myoepithelial cells, increasing intracellular calcium and promoting uterine contractions and milk ejection.
Indications / reported uses
  • Historically used in some countries for induction or augmentation of uterine contractions and to support lactation; current authorisation, obstetric use and safety criteria are jurisdiction-specific

Sources: NLM MeSH — Demoxytocin · PubMed — Demoxytocin oxytocin analogue · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Demoxytocin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Demoxytocin Permitted Daily Exposure (PDE) report (the Demoxytocin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Demoxytocin Occupational Exposure Limit (OEL) report (the Demoxytocin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.